TCTMD’s Top 10 Most Popular Stories for January 2018

This month, a feature examining sexual harassment in the cardiology profession ran away with the top-story spot. Other stories spanned a wide range of topics including the role and prognostic value of Lp(a) in CVD; how and when to “de-escalate” dual antiplatelet therapy in ACS; a US Food and Drug Administration alert about clopidogrel tablets that might contain a statin instead; and the print publication of REPRISE III. Also on the list for January 2018: friends and colleagues of Steven Sedlis, MD, mourn the loss of a mentor and patient advocate.

#CardiologyToo? Sexual Harassment Also Infects Hospital Corridors and the Cath Lab

Tales of workplace sexual harassment and inappropriate interview questions within cardiology hint that the halls of medicine have their own secrets.

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

A new review provides direction on everything from standardizing assay values to large-scale testing of new therapies that lower Lp(a) levels.

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

While guidelines suggest sticking to a more potent antiplatelet regimen for a year, physicians are faced with many real-world reasons to switch earlier.

Recall: Clopidogrel Tablets Mislabeled, May Contain Statin

The single lot being recalled was distributed nationwide and may contain simvastatin instead of clopidogrel.

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

The publication compares the first-generation mechanically expanded TAVR system to a first- and second-generation self-expanding device.

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

The report provides information on everything from how to start, add, or switch therapy to integrating palliative/hospice care.

Registry Challenges LVEF Cutoff for AVR, With Implications for Asymptomatic Patients

Experts say a new analysis from CURRENT AS helps shed light on the timing of aortic valve replacement, particularly in patients without symptoms.

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

The findings “are going to fundamentally change the way we approach prevention,” the author says. But one expert calls for more data.

Steven Sedlis, Cardiology Leader and Mentor, Dies at 65

The prolific clinician-investigator was known for his leadership at the Manhattan VA Medical Center and a passion for social justice.